Black Diamond Therapeutics Inc (BDTX) — Cash Flow Reinvestment Rate

Latest as of March 2025: 0.16x

Black Diamond Therapeutics Inc (BDTX) has a Cash Flow Reinvestment Rate of 0.16x as of March 2025, reinvesting $8.55 Million (capex $0.00 plus investments $8.55 Million) from operating cash flow of $53.41 Million. See how leveraged is Black Diamond Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.

Reinvestment Rate

0.16x

(Capex + Investments) / Operating CF

Total Reinvested

$8.55 Million

Capex + Investments

Operating Cash Flow

$53.41 Million

USD

Capital Expenditures

$0.00

USD

Black Diamond Therapeutics Inc Cash Flow Reinvestment Rate (2025–2025)

Historical reinvestment intensity for Black Diamond Therapeutics Inc across 1 annual periods. Also explore how large is Black Diamond Therapeutics Inc's balance sheet for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Black Diamond Therapeutics Inc (2025–2025)

Year-by-year capital reinvestment analysis for Black Diamond Therapeutics Inc. For live market cap and broader valuation context, see BDTX market cap overview.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2025	1.52x	$44.93 Million	$29.61 Million	$0.00	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow